Table 1.
Participant demographics and baseline characteristics.
| Characteristic | V114 (n = 152) | PCV13 (n = 150) |
| Age, mean (range) (years) | 42.4 (23–74) | 41.3 (21–69) |
| Sex [n (%)] | ||
| Male | 120 (78.9) | 118 (78.7) |
| Female | 32 (21.1) | 32 (21.3) |
| Race [n (%)] | ||
| Black or African American | 51 (33.6) | 43 (28.7) |
| White | 41 (27.0) | 48 (32.0) |
| Multiple | 36 (23.7) | 26 (17.3) |
| Asian | 24 (15.8) | 30 (20.0) |
| Native Hawaiian or other Pacific Islander | 0 (0.0) | 2 (1.3) |
| American Indian or Alaska native | 0 (0.0) | 1 (0.7) |
| Ethnicity [n (%)] | ||
| Not Hispanic or Latino | 102 (67.1) | 104 (69.3) |
| Hispanic or Latino | 49 (32.2) | 45 (30.0) |
| Not reported | 1 (0.7) | 1 (0.7) |
| Antiretroviral therapy [n (%)] | 152 (100) | 150 (100) |
| CD4+ T-cell count [n (%)] | ||
| ≥500 cells/μl | 74 (48.7) | 72 (48.0) |
| ≥200 to <500 cells/μl | 76 (50.0) | 76 (50.7) |
| ≥50 to <200 cells/μl | 2 (1.3) | 2 (1.3) |
| HIV RNA [n (%)] | ||
| <20 copies/ml | 123 (80.9) | 114 (76.0) |
| ≥20 copies/mla | 29 (19.1) | 36 (24.0) |
CD, cluster of differentiation; PCV13, 13-valent pneumococcal conjugate vaccine; RNA, ribonucleic acid; V114, 15-valent pneumococcal conjugate vaccine.
a
Maximum less than 50 000 copies/ml, per protocol.